Inactivated Poliovirus Vaccine | Community Health

The inactivated poliovirus vaccine (IPV) is a vital component in the global effort to eradicate polio, a highly infectious disease that can cause paralysis and death. Developed through the inactivation of poliovirus, IPV is administered via injection, typically in a series of doses during childhood. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) recommend the use of IPV as part of a comprehensive vaccination strategy to protect against polio. With its high efficacy and safety profile, IPV has been instrumental in reducing polio cases worldwide from an estimated 350,000 in 1988 to just 33 in 2018. The vaccine's impact is a testament to the power of global health initiatives and the importance of continued vaccination efforts to ensure polio remains a disease of the past. As of 2022, the global community continues to work towards polio eradication, with IPV playing a central role in this endeavor. The WHO, CDC, and other health organizations are committed to maintaining high vaccination coverage and addressing the challenges posed by circulating vaccine-derived poliovirus (cVDPV), a form of the vaccine virus that has reverted to causing polio-like symptoms in rare instances.